




Partner in Academic Medicine



Eng Eong Ooi, BMBS PhD FRCPATH
Professor
Program in Emerging Infectious Diseases
Duke-NUS Medical School

BNT162b2 show efficacy ~2 weeks after 1st dose



New Data (collected by Duke-NUS Medical School; manuscript submitted)

- Singapore healthcare workers (N = 20) received a single shot (30 µg) of mRNA vaccine (BNT162b2)

Compared to previously collected data

- Singapore participants (N = 22) received a single shot (5 µg) of self-amplifying mRNA vaccine (ARCT-021)

Data collected by Duke-NUS Medical School – utilizing the same assays



		Day	BNT162b2 (30 µg); N = 20	ARCT-021 (5 µg); N = 22
Humoral Immunity	Binding Antibodies	IgG (4-fold rises)	Day 10: 80%	--
			Day 14: --	81%
	Neutralizing Antibodies	PRNT (% Detectable)	Day 10: 10%*	--
			Day 28: --	59%**
Cellular Immunity	T cells	ELISpot (SFUs)	Day 10: 28	--
		<i>Median change from baseline</i>	Day 15: --	211
			Day 21: 13	--

SFUs = Spot Forming Units per million peripheral blood mononuclear cells

PRNT = plaque reduction neutralization test

*lower threshold (dilution of 10)

**higher threshold (dilution of 20)

This new data combined with recent reports of mRNA vaccines being effective after a single administration increases the probability of success for ARCT-021 in upcoming Phase 3 efficacy study